Abstract
Background Engineering controls are a necessity for minimising aerosol transmission of SARS-CoV-2, yet so far, little attention has been given to such interventions. High flow local extraction (HFLE) is a standard in other industries that deal with airborne contaminants.
Objective This study aims to provide a quantitative evaluation of an HFLE concept feasible to implement in most real clinical settings.
Design A unique combined experimental model of Laser sheet illumination videography paired with continuous nanoparticle counts was used to quantitatively assess the impact of HFLE in an operating theatre. Propylene Glycol was aerosolised via a customised physiological lung simulator and dispersion was measured in 3 dimensions. Cumulative probability heat maps were generated to describe aerosol behaviour. Continuous particle counts were made at 15 locations throughout the room to validate laser assessments.
Results High flow local extraction reduced dispersion of simulated exhaled aerosols to undetectable levels. With the HFLE in operation and optimally positioned, the aerosol plume was tightly controlled. Particle counts remained at baseline when HFLE was active. HFLE becomes less effective when positioned at increasing distance from the mouth.
Aerosol plume behaviour in the absence of HFLE was highly variable and unpredictable.
Conclusions This analysis demonstrates great potential for HFLE to have a significant impact in reducing aerosol transmission. Simple HFLE devices can be easily engineered and could be widely deployed without impacting on the safe delivery of care.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
No external funding was involved in this study.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
NA - no human subjects involved.
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
Full data sets and raw video files are available on request